Related Experiment Video
Updated: Mar 15, 2026

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry
Published on: July 13, 2019
Molecular mechanisms supporting a pathogenic role for human polyomavirus 6 small T antigen: Protein phosphatase 2A
Julie H Wu1,2, Rebecca A Simonette1, Harrison P Nguyen1,2
1Department of Dermatology, University of Texas Health Science Center, Houston, Texas.
Abstract:
BRAF inhibitors are highly effective therapies in treating a subset of melanomas but are associated with induction of secondary cutaneous squamous cell carcinoma (cSCC). Recently, Human Polyomavirus 6 (HPyV6) was found to actively express viral proteins in BRAF inhibitor-induced cSCCs; however, the specific cellular mechanisms by which HPyV6 may facilitate neoplastic cell growth require further investigation. The current study describes a novel pathogenic mechanism of action for HPyV6 small tumor (sT) antigen which involves binding to protein phosphatase 2A (PP2A) via its WFG motif and zinc binding sites. Our findings demonstrate an important role of HPyV6 sT for activation of PP2A's downstream oncogenic pathways (MEK/ERK/c-Jun), which may underlie the pathogenesis of BRAF inhibitor-induced neoplasms. J. Med. Virol. 89:742-747, 2017. © 2016 Wiley Periodicals, Inc.
Insights
Human Polyomavirus 6 (HPyV6) small tumor antigen activates protein phosphatase 2A (PP2A), driving oncogenic pathways. This mechanism may explain how HPyV6 contributes to secondary skin cancers in BRAF inhibitor melanoma treatments.
Area of Science:
- Oncology
- Virology
- Dermatology
Background:
- BRAF inhibitors treat melanoma but can cause secondary cutaneous squamous cell carcinoma (cSCC).
- Human Polyomavirus 6 (HPyV6) proteins are found in BRAF inhibitor-induced cSCCs.
- The mechanism by which HPyV6 promotes neoplastic growth is unclear.
Purpose of the Study:
- To investigate the pathogenic mechanism of HPyV6 small tumor (sT) antigen in BRAF inhibitor-induced neoplasms.
- To elucidate the interaction between HPyV6 sT and cellular proteins involved in cancer development.
Main Methods:
- Investigated the binding of HPyV6 sT antigen to protein phosphatase 2A (PP2A).
- Analyzed the role of HPyV6 sT antigen's WFG motif and zinc binding sites in PP2A interaction.
- Examined the activation of downstream oncogenic pathways (MEK/ERK/c-Jun) by HPyV6 sT-PP2A interaction.
Main Results:
- HPyV6 sT antigen binds to PP2A via its WFG motif and zinc binding sites.
- HPyV6 sT antigen activates PP2A.
- Activation of PP2A by HPyV6 sT leads to the activation of downstream oncogenic pathways, including MEK/ERK/c-Jun.
Conclusions:
- HPyV6 sT antigen plays a significant role in the pathogenesis of BRAF inhibitor-induced neoplasms.
- The interaction between HPyV6 sT and PP2A activates oncogenic signaling pathways.
- This study reveals a novel mechanism for HPyV6 in promoting cancer development.
Related Concept Videos
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
Mechanisms of Retrovirus-induced Cancers
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

